Insulin resistance by homeostatic model assessment in patients of polycystic ovarian syndrome

Authors

  • Aishwarya S. Jadhav Department of Obstetrics and Gynaecology, Ashwini Medical College, Hospital and Research Centre, Solapur, Maharashtra, India
  • Rajiv T. Dabade Department of Obstetrics and Gynaecology, Ashwini Medical College, Hospital and Research Centre, Solapur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20250879

Keywords:

Polycystic ovarian syndrome, Insulin resistance, HOMA-IR, BMI

Abstract

Polycystic ovarian syndrome (PCOS) is one of the common endocrine disorders of reproductive age and affects approximately 6-16% of general population. Considering high incidence (70-95%) of insulin resistance in women with high BMI, 30-75% of population is found to have insulin resistance inspite of being lean. So, it is worth proving insulin resistance irrespective of BMI. Of amongst different tests to diagnose insulin resistance, homeostatic model assessment of insulin resistance (HOMA-IR) has been proved to be useful as a screening test for insulin resistance. This is a retrospective observational study of 4 months from April 2022 to July 2022 and included 18 patients diagnosed with PCOS. We studied their BMI, fasting glucose, fasting insulin and HOMA-IR. Out of total patients screened, the prevalence of insulin resistance was 72.22% as calculated by HOMA-IR test. No prevalence of HOMA-IR was observed in underweight cases. Out of normal weight cases, 83.33% cases were found to have Insulin resistance. Of the overweight and obese cases, 100% were found to have insulin resistance. Majority of women with PCOS have insulin resistance and consequent hyperinsulinemia. Insulin resistance is directly proportional to weight gain in PCOS patients. Lifestyle modification and administration of insulin sensitizers like Metformin is useful in reducing insulin resistance in overweight and obese patients. In patients with normal BMI who prove to have insulin resistance with raised HOMA-IR test are also benefited from medical therapy.

Metrics

Metrics Loading ...

Author Biography

Rajiv T. Dabade, Department of Obstetrics and Gynaecology, Ashwini Medical College, Hospital and Research Centre, Solapur, Maharashtra, India

Department of Obstetrics and Gynaecology

References

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15. DOI: https://doi.org/10.1016/j.fertnstert.2016.05.003

Eshre TR. Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility. 2004;81(1):19-25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004

American Diabetes Association. Lifestyle management: standards of medical care in diabetes-2019. Diabetes care. 2019;42(1):46-60. DOI: https://doi.org/10.2337/dc19-S005

Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139-46. DOI: https://doi.org/10.1210/jc.85.1.139

Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-74. DOI: https://doi.org/10.2337/diabetes.38.9.1165

Catherine Marin DeUgarte, Alfred A. Bartolucci. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertnstert. 2005;83:1454-60. DOI: https://doi.org/10.1016/j.fertnstert.2004.11.070

Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2. DOI: https://doi.org/10.2337/diacare.21.12.2191

Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Syst Rev. 2007;2:5552. DOI: https://doi.org/10.1002/14651858.CD005552.pub2

Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med. 2002;19:724–9. DOI: https://doi.org/10.1046/j.1464-5491.2002.00794.x

Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance. Fertil Steril. 2012;97(1):18-22. DOI: https://doi.org/10.1016/j.fertnstert.2011.11.036

Downloads

Published

2025-03-27

How to Cite

Jadhav, A. S., & Dabade, R. T. (2025). Insulin resistance by homeostatic model assessment in patients of polycystic ovarian syndrome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 14(4), 1307–1310. https://doi.org/10.18203/2320-1770.ijrcog20250879

Issue

Section

Case Series